School of Medicine


Showing 91-100 of 4,395 Results

  • Alawab Aldulimy

    Alawab Aldulimy

    Clinical Rsch Coord Assoc, CV Med - Clinical Trials

    Current Role at StanfordClinical Researcher

    Clinical Research Coordinator

  • William Alegria

    William Alegria

    Lecturer, Medicine - Med/Infectious Diseases

    BioDr. Alegria is a board-certified Infectious Diseases Pharmacotherapy specialist and antimicrobial stewardship consultant with the Stanford Antimicrobial Safety and Sustainability Program. He primarily practices in the inpatient setting and is dedicated to developing targeted stewardship interventions in immunocompromised patient populations. His clinical interests include management of infections in immunocompromised hosts, antifungal pharmacotherapy, and difficult-to-treat infections.

    Publications (selected)

    Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead. Arya R, Zimmet AN, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025

    How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians. Prasad R, Arya R, Meng L, Holubar M, Alegria W, Zimmet AN.
    Antimicrob Steward Healthc Epidemiol. 2025

    Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients. Prasad R, Lu B, Veloria D, Mui E, Nelson J, Dhillon G, Deresinski S, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025

    No "One-Size-Fits All": chronic "Carryover" diagnoses dilute antibiotic prescribing rates for sinusitis among adults in primary and urgent care settings. Smith M, Hawkins M, Laikijrung C, Mui E, Alegria W, Leung T, Zimmet A, Ha D, Holubar M. Infect Control Hosp Epidemiol. 2024

    Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Lu B, Ha D, Shen S, Ferguson Toll J, Kim A, Kim S, Mui E, Deresinski S, Holubar M, Alegria W. Open Forum Infect Dis. 2024

    "Electronic Phenotyping" Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal Transplant. Zimmet AN, Ha D, Mui E, Smith M, Hawkins M, Alegria W, Holubar M. Open Forum Infect Dis. 2024

    Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia. Fox E, Ha D, Bounthavong M, Meng L, Mui E, Holubar M, Deresinski S, Alegria W. BMC Infect Dis. 2022

    Shorter durations of antibiotic therapy in organ transplant. Alegria W, Medvedeva N, Holubar M. Curr Opin Organ Transplant. 2022

    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Br J Haematol. 2022

    Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Alegria W, Marini BL, Gregg KS, Bixby DL, Perissinotti A, Nagel J. J Natl Compr Canc Netw. 2022

    Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Diep C, Meng L, Pourali S, Hitchcock MM, Alegria W, Swayngim R, Ran R, Banaei N, Deresinski S, Holubar M. Am J Health Syst Pharm. 2021 Dec

    The Current State of Antifungal Stewardship in Immunocompromised Populations. Alegria W, Patel PK. J Fungi (Basel). 2021

    Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Holubar M, Meng L, Alegria W, Deresinski S. Infect Dis Clin North Am. 2020

    Impact of Rapid Antimicrobial Susceptibility Testing in Gram-Negative Rod Bacteremia: a Quasi-experimental Study. Hogan CA, Ebunji B, Watz N, Kapphahn K, Rigdon J, Mui E, Meng L, Alegria W, Holubar M, Deresinski S, Banaei N. J Clin Microbiol. 2020

    Antimicrobial Stewardship in Cancer Patients: The Time is Now. Aitken SL, Nagel JL, Abbo L, Alegria W, Barreto JN, Dadwal S, Freifeld AG, Jain R, Pergam SA, Tverdek FP, Seo SK; Antimicrobial Stewardship in Cancer Consortium ASCC. J Natl Compr Canc Netw. 2019

  • Dr. Lydia Aletraris

    Dr. Lydia Aletraris

    Social Science Research Scholar, Health Policy

    BioDr. Lydia Aletraris brings both a national and global perspective to her research, specializing in substance use and human trafficking. With extensive experience managing projects funded by agencies such as the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the U.S. Department of Justice, and the U.S. Department of State, she has served as Principal Investigator or Co-Principal Investigator on national research examining the implementation of evidence-based practices in substance use treatment and the effects of U.S. cannabis policy, as well as on international research focused on human trafficking.

    Dr. Aletraris previously coordinated the Prevalence Reduction Innovation Forum (PRIF), a global initiative that developed key trafficking indicators and brought together scholars from around the world to test methodologies for measuring human trafficking prevalence, with studies conducted in Brazil, Costa Rica, Morocco, Pakistan, Tanzania, and Tunisia.

    With a commitment to health and human rights, her research addresses urgent public health challenges through ethical, evidence-based practices and policies that support resilience and recovery across diverse, at-risk populations. Dr. Aletraris holds a PhD in Sociology from the University of Georgia.

  • Mostafa H. Algabri

    Mostafa H. Algabri

    Visiting Instructor,

    BioMostafa Hikmat Saeed Algabri, M.B.Ch.B., is a physician and clinical researcher currently serving as a visiting instructor in the Department of Neurosurgery at Stanford University School of Medicine. His research focuses on stereotactic radiosurgery (SRS), neurovascular disease, and advanced neuroimaging, with particular interest in evaluating the outcomes, indications, and adverse effects of radiosurgical interventions in neurosurgical disorders such as arteriovenous malformations, vestibular schwannomas, meningiomas, and paragangliomas.

    Dr. Algabri graduated from the College of Medicine at the University of Baghdad and is ECFMG-certified. He successfully completed the United States Medical Licensing Examination (USMLE) steps 1 and 2 (CK). He has authored numerous peer-reviewed publications in neurosurgery, neurology, and neuroradiology journals and actively collaborates on international research projects involving cerebrovascular disease, spine surgery, and neurosurgical outcomes research.

    In addition to his work at Stanford, Dr. Algabri serves as a peer reviewer for several scientific journals, including World Neurosurgery, World Neurosurgery: X, Journal of Clinical Neuroscience, Interdisciplinary Neurosurgery, and Cureus.

    Dr. Algabri is the founder of the NeuroResearch Circle academic platform and the developer of the Stroke Localizer educational system designed to teach stroke localization and neuroanatomy through interactive learning. His research has been presented at international scientific meetings, including the Congress of Neurological Surgeons (CNS), the Academic International Medical Summit (AIMS), and the International Student Congress of (Bio)Medical Sciences (ISCOMS). In 2025, he received the Ideal Physician Award from the Iraqi Medical Association in recognition of his dedication to patient care, professionalism, and contributions to academic medicine.